Novo Nordisk A/S
CSE:NOVO B
Novo Nordisk A/S
Revenue
Novo Nordisk A/S
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novo Nordisk A/S
CSE:NOVO B
|
Revenue
kr290.4B
|
CAGR 3-Years
27%
|
CAGR 5-Years
19%
|
CAGR 10-Years
13%
|
|
|
H Lundbeck A/S
CSE:HLUN A
|
Revenue
kr22B
|
CAGR 3-Years
11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ALK-Abello A/S
CSE:ALK B
|
Revenue
kr5.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
S
|
Stenocare A/S
CSE:STENO
|
Revenue
kr2.2m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
Novo Nordisk A/S
Glance View
In the heart of Denmark, Novo Nordisk A/S stands as a beacon of innovation in the pharmaceutical industry, tracing its roots back to the early 20th century when it began as a small insulin-producing laboratory. This company, now a global heavyweight, is renowned for its dedication to diabetes care, a commitment that has driven its meteoric rise. Novo Nordisk's operations are deeply entrenched in the discovery, development, and production of medicines aimed at treating chronic diseases such as diabetes, obesity, and rare blood and endocrine disorders. Their prowess in biotechnology is not only evident in their diverse product portfolio but also in their relentless pursuit of new therapeutics through cutting-edge research and development, underscoring their mantra of improving the quality of life for millions across the globe. At its core, Novo Nordisk's business model is a sophisticated blend of patient-centric innovation and strategic market outreach. Sales of insulin and GLP-1 receptor agonists form the backbone of their revenue, targeting a growing global demographic faced with diabetes and related metabolic conditions. Their manufacturing process is a finely-tuned system that transforms complex scientific discoveries into tangible, effective treatments. Through strategic pricing, partnerships, and expansion in both mature and emerging markets, Novo Nordisk skillfully maneuvers the intricate web of global healthcare demands. By leveraging a robust pipeline of new drugs and improving access to existing therapies, the company not only secures its financial health but also ensures that its impact on healthcare remains profound and far-reaching.
See Also
What is Novo Nordisk A/S's Revenue?
Revenue
290.4B
DKK
Based on the financial report for Dec 31, 2024, Novo Nordisk A/S's Revenue amounts to 290.4B DKK.
What is Novo Nordisk A/S's Revenue growth rate?
Revenue CAGR 10Y
13%
Over the last year, the Revenue growth was 25%. The average annual Revenue growth rates for Novo Nordisk A/S have been 27% over the past three years , 19% over the past five years , and 13% over the past ten years .
You don't have any saved screeners yet